A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Overview[ - collapse ][ - ]

Purpose The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB) of diffuse large B-cell lymphoma (DLBCL).
ConditionLymphoma
InterventionDrug: Ibrutinib
Drug: Placebo
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone (or equivalent)
PhasePhase 3
SponsorJanssen Research & Development, LLC
Responsible PartyJanssen Research & Development, LLC
ClinicalTrials.gov IdentifierNCT01855750
First ReceivedMay 14, 2013
Last UpdatedApril 24, 2014
Last verifiedApril 2014

Tracking Information[ + expand ][ + ]

First Received DateMay 14, 2013
Last Updated DateApril 24, 2014
Start DateSeptember 2013
Estimated Primary Completion DateJune 2020
Current Primary Outcome MeasuresEvent-free survival [Time Frame: Up to disease progression, relapse from complete response, initiation of subsequent systemic antilymphoma therapy after completion of at least 6 cycles of R-CHOP therapy, or death, whichever occurs first, up to Year 7] [Designated as safety issue: No]
Current Secondary Outcome Measures
  • Progression-free survival [Time Frame: Up to disease progression, relapse from complete response, or death, whichever occurs first, up to Year 7] [Designated as safety issue: No]
  • Overall survival [Time Frame: Up to the date of the participants death, up to Year 7] [Designated as safety issue: No]
  • Complete response rate [Time Frame: Up to completion of chemotherapy treatment, up to Year 7] [Designated as safety issue: No]
  • Time to worsening symptoms in the Lym subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) [Time Frame: Up to the start date of the worsening of patient symptoms, up to Year 7] [Designated as safety issue: No]
  • Oral plasma clearance of ibrutinib [Time Frame: Predose Day 1 of Cycles 1, 2, and 3, and postdose 1 h, 2 h, and 4 h of Cycles 1 and 2] [Designated as safety issue: No]
  • Oral volume of distribution at steady state of ibrutinib [Time Frame: Predose Day 1 of Cycles 1, 2, and 3, and postdose 1 h, 2 h, and 4 h of Cycles 1 and 2] [Designated as safety issue: No]
  • Area under the plasma concentration-time curve of ibrutinib [Time Frame: Predose Day 1 of Cycles 1, 2, and 3, and postdose 1 h, 2 h, and 4 h of Cycles 1 and 2] [Designated as safety issue: No]
  • Minimum observed plasma concentration of ibrutinib [Time Frame: Predose Day 1 of Cycles 1, 2, and 3, and postdose 1 h, 2 h, and 4 h of Cycles 1 and 2] [Designated as safety issue: No]
  • Number of participants affected by an adverse event [Time Frame: Up to 30 days after the last dose of study medication] [Designated as safety issue: Yes]

Descriptive Information[ + expand ][ + ]

Brief TitleA Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Official TitleA Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Brief Summary
The purpose of this study is to evaluate if ibrutinib administered in combination with
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the
clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB)
of diffuse large B-cell lymphoma (DLBCL).
Detailed Description
This is a randomized (individuals assigned to study treatment by chance), double-blind
(individuals and study personnel will not know the identity of study treatments), placebo
(an inactive substance that is compared with a drug to test whether the drug has a real
effect in a clinical trial)-controlled study to compare the efficacy and safety of ibrutinib
in combination with R-CHOP versus R-CHOP alone in adult patients newly diagnosed non-GCB
DLBCL. The study will include screening, active treatment, and posttreatment follow-up
phases. The study will end when 50% of participants have died or the sponsor terminates the
study, whichever occurs first (up to approximately 7 years). Approximately 800 participants
will be randomly assigned in a 1:1 ratio to receive either placebo+R-CHOP (treatment arm A)
or ibrutinib+R-CHOP (treatment arm B). All participants will receive R-CHOP as background
therapy for 6 or 8 cycles (21 days per cycle) prespecified according to local practice.
After 4 treatment cycles, an interim response assessment will be performed to evaluate
disease progression for each participant. Participants with progressive disease or relapsed
disease after complete response will be discontinued from treatment. Participants who
discontinue R-CHOP without disease progression will continue study drug (placebo or
ibrutinib) until 6 or 8 cycles are completed, disease progression, or unacceptable toxicity,
whichever occurs first. After completion of study drug, participants will undergo assessment
of tumor response based on the Revised Response Criteria for Malignant Lymphoma.
Participants with documented residual disease upon completion of at least 6 cycles of R-CHOP
therapy are considered eligible to initiate subsequent antilymphoma therapy. Serial
pharmacokinetic samples will be collected before and after dosing, and safety will be
monitored throughout the study.
Study TypeInterventional
Study PhasePhase 3
Study DesignAllocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
ConditionLymphoma
InterventionDrug: Ibrutinib
560 mg capsules administered by mouth once daily (21-day cycles)
Drug: Placebo
4 matched capsules administered by mouth once daily (21-day cycles)
Drug: Rituximab
375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Drug: Cyclophosphamide
750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Drug: Doxorubicin
50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Drug: Vincristine
1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Drug: Prednisone (or equivalent)
100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
Study Arm (s)
  • Placebo Comparator: Treatment Arm A: placebo + R-CHOP
    Treatment Arm A = placebo + R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)
  • Experimental: Treatment Arm B: ibrutinib + R-CHOP
    Treatment Arm B = ibrutinib + R-CHOP

Recruitment Information[ + expand ][ + ]

Recruitment StatusRecruiting
Estimated Enrollment800
Estimated Completion DateJune 2020
Estimated Primary Completion DateJune 2018
Eligibility Criteria
Inclusion Criteria:

- No prior treatment for diffuse B-cell lymphoma (DLBCL)

- Histologically-confirmed non-germinal center B-cell subtype DLBCL

- Stage II (not candidates for local x-ray therapy), III, or IV disease by the Ann
Arbor Classification

- At least 1 measurable site of disease according to Revised Response Criteria for
Malignant Lymphoma

- Revised International Prognostic Index score of >=1

- Eastern Cooperative Oncology Group performance status grade of 0, 1, or 2

- Hematology and biochemical laboratory values within protocol-defined parameters
within 14 days prior to random assignment and at baseline

- Left ventricular ejection fraction within institutional normal limits, as determined
by echocardiography or multiple uptake gated acquisition (MUGA) scan

- Agrees to protocol-defined use of effective contraception (for women, these
restrictions apply for 12 months after the last dose of rituximab or 1 month after
the last dose of study drug, whichever is later; for men, these restrictions apply
for 12 months after the last dose of rituximab or 3 months after the last dose of
study drug, whichever is later)

- Men must agree to not donate sperm during and after the study for 12 months after the
last dose of rituximab or 3 months after the last dose of study drug, whichever is
later

- Women of childbearing potential must have a negative serum or urine pregnancy test at
screening

Exclusion Criteria:

- Major surgery within 4 weeks of random assignment

- Known central nervous system or primary mediastinal lymphoma

- Prior history of indolent lymphoma

- Diagnosed or treated for malignancy other than DLBCL, except: malignancy treated with
curative intent and with no known active disease present for >=3 years before random
assignment; adequately treated non-melanoma skin cancer or lentigo maligna without
evidence of disease; adequately treated carcinoma in situ without evidence of disease

- History of stroke or intracranial hemorrhage within 6 months prior to random
assignment

- Requires anticoagulation with warfarin or equivalent vitamin K antagonists

- Requires treatment with strong CYP3A inhibitors

- Prior anthracycline use >=150 mg/m2

- Clinically significant cardiovascular disease such as uncontrolled or symptomatic
arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined
by the New York Heart Association Functional Classification

- Known history of human immunodeficiency virus or active hepatitis C virus or active
hepatitis B virus infection or any uncontrolled active systemic infection requiring
intravenous antibiotics

- Women who are pregnant or breastfeeding

- Any life-threatening illness, medical condition, or organ system dysfunction which,
in the investigator's opinion, could compromise the patient's safety, interfere with
the absorption or metabolism of ibrutinib capsules, or put the study outcomes at
undue risk
GenderBoth
Ages18 Years
Accepts Healthy VolunteersNo
ContactsContact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:
JNJ.CT@sylogent.com
Location CountriesUnited States, Argentina, Australia, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Japan, Korea, Republic of, Mexico, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom

Administrative Information[ + expand ][ + ]

NCT Number NCT01855750
Other Study ID NumbersCR102118
Has Data Monitoring CommitteeYes
Information Provided ByJanssen Research & Development, LLC
Study SponsorJanssen Research & Development, LLC
CollaboratorsPharmacyclics
Investigators Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
Verification DateApril 2014

Locations[ + expand ][ + ]

United States, Arizona
Tucson, Arizona, United States
Not yet recruiting
United States, California
Burbank, California, United States
Withdrawn
United States, California
Greenbrae, California, United States
Recruiting
United States, California
La Jolla, California, United States
Not yet recruiting
United States, California
Los Angeles, California, United States
Withdrawn
United States, California
Los Angeles, California, United States
Not yet recruiting
United States, California
Salinas, California, United States
Recruiting
United States, California
Stanford, California, United States
Not yet recruiting
United States, Connecticut
Danbury, Connecticut, United States
Recruiting
United States, Connecticut
Hartford, Connecticut, United States
Recruiting
United States, Connecticut
Middletown, Connecticut, United States
Withdrawn
United States, District of Columbia
Washington, District of Columbia, United States
Recruiting
United States, Florida
Palm Beach Gardens, Florida, United States
Withdrawn
United States, Florida
Tampa, Florida, United States
Withdrawn
United States, Georgia
Atlanta, Georgia, United States
Recruiting
United States, Georgia
Marietta, Georgia, United States
Recruiting
United States, Idaho
Post Falls, Idaho, United States
Withdrawn
United States, Illinois
Chicago, Illinois, United States
Withdrawn
United States, Illinois
Maywood, Illinois, United States
Withdrawn
United States, Illinois
Peoria, Illinois, United States
Recruiting
United States, Indiana
Fort Wayne, Indiana, United States
Recruiting
United States, Indiana
Goshen, Indiana, United States
Recruiting
United States, Indiana
Indianapolis, Indiana, United States
Recruiting
United States, Kansas
Topeka, Kansas, United States
Recruiting
United States, Kentucky
Louisville, Kentucky, United States
Recruiting
United States, Louisiana
Baton Rouge, Louisiana, United States
Recruiting
United States, Louisiana
Metairie, Louisiana, United States
Withdrawn
United States, Louisiana
New Orleans, Louisiana, United States
Recruiting
United States, Maryland
Baltimore, Maryland, United States
Withdrawn
United States, Maryland
Baltimore, Maryland, United States
Recruiting
United States, Maryland
Bethesda, Maryland, United States
Recruiting
United States, Maryland
Bethesda, Maryland, United States
Not yet recruiting
United States, Maryland
Rockville, Maryland, United States
Withdrawn
United States, Massachusetts
Boston, Massachusetts, United States
Recruiting
United States, Massachusetts
Boston, Massachusetts, United States
Withdrawn
United States, Massachusetts
Boston, Massachusetts, United States
Not yet recruiting
United States, Michigan
Ann Arbor, Michigan, United States
Recruiting
United States, Missouri
St. Louis, Missouri, United States
Recruiting
United States, Nebraska
Omaha, Nebraska, United States
Not yet recruiting
United States, New Jersey
Hackensack, New Jersey, United States
Recruiting
United States, New Jersey
New Brunswick, New Jersey, United States
Recruiting
United States, New York
Bronx, New York, United States
Recruiting
United States, New York
Fresh Meadows, New York, United States
Recruiting
United States, New York
Johnson City, New York, United States
Recruiting
United States, New York
Mineola, New York, United States
Recruiting
United States, New York
New York, New York, United States
Recruiting
United States, New York
New York, New York, United States
Not yet recruiting
United States, New York
Rochester, New York, United States
Recruiting
United States, North Carolina
Charlotte, North Carolina, United States
Not yet recruiting
United States, North Carolina
Charlotte, North Carolina, United States
Recruiting
United States, North Carolina
Goldsboro, North Carolina, United States
Withdrawn
United States, North Carolina
Greenville, North Carolina, United States
Recruiting
United States, North Carolina
Hickory, North Carolina, United States
Recruiting
United States, Ohio
Cincinnati, Ohio, United States
Withdrawn
United States, Ohio
Columbus, Ohio, United States
Not yet recruiting
United States, Oregon
Portland, Oregon, United States
Recruiting
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
Withdrawn
United States, Pennsylvania
Pittsburgh, Pennsylvania, United States
Withdrawn
United States, South Carolina
N Charleston, South Carolina, United States
Recruiting
United States, Tennessee
Nashville, Tennessee, United States
Withdrawn
United States, Tennessee
Nashville, Tennessee, United States
Not yet recruiting
United States, Texas
Houston, Texas, United States
Not yet recruiting
United States, Texas
Houston, Texas, United States
Recruiting
United States, Texas
Temple, Texas, United States
Recruiting
United States, Utah
Salt Lake City, Utah, United States
Withdrawn
United States, Vermont
Burlington, Vermont, United States
Recruiting
United States, Virginia
Charlottesville, Virginia, United States
Withdrawn
United States, Washington
Seattle, Washington, United States
Not yet recruiting
United States, Wisconsin
Marshfield, Wisconsin, United States
Withdrawn
Argentina
Buenos Aires, Argentina
Recruiting
Argentina
Capital Federal, Argentina
Withdrawn
Argentina
Ciudad Autonoma Buenos Aires, Argentina
Recruiting
Argentina
Ciudad De Buenos Aires, Argentina
Recruiting
Argentina
Cordoba, Argentina
Not yet recruiting
Argentina
Córdoba, Argentina
Withdrawn
Argentina
La Capital, Argentina
Recruiting
Argentina
La Plata, Argentina
Not yet recruiting
Argentina
Parana, Argentina
Withdrawn
Australia
Adelaide, Australia
Recruiting
Australia
Concord, Australia
Recruiting
Australia
Darlinghurst, Australia
Recruiting
Australia
Douglas, Australia
Withdrawn
Australia
Freemantle, Australia
Recruiting
Australia
Hobart, Tasmania, Australia
Recruiting
Australia
Melbourne, Australia
Recruiting
Australia
Nedlands, Australia
Recruiting
Australia
Perth, Australia
Withdrawn
Australia
Randwick, Australia
Recruiting
Australia
South Brisbane, Australia
Recruiting
Australia
Woden, Australia
Withdrawn
Australia
Woolloongabba, Australia
Recruiting
Belgium
Antwerpen, Belgium
Recruiting
Belgium
Brugge, Belgium
Recruiting
Belgium
Brussel, Belgium
Recruiting
Belgium
Gent, Belgium
Recruiting
Belgium
Haine-Saint-Paul, La Louviere, Belgium
Recruiting
Belgium
Kortrijk, Belgium
Recruiting
Belgium
Leuven, Belgium
Recruiting
Brazil
Brasília, Brazil
Withdrawn
Brazil
Campinas, Brazil
Withdrawn
Brazil
Curitiba, Brazil
Withdrawn
Brazil
Jau, Brazil
Withdrawn
Brazil
Porto Alegre, Brazil
Withdrawn
Brazil
Porto Alegre, Brazil
Not yet recruiting
Brazil
Ribeirão Preto, Brazil
Withdrawn
Brazil
Rio De Janeiro, Brazil
Not yet recruiting
Brazil
Sao Paulo, Brazil
Not yet recruiting
Brazil
Sao Paulo, Brazil
Recruiting
Brazil
São José Do Rio Preto, Brazil
Withdrawn
Brazil
São Paulo, Brazil
Not yet recruiting
Canada, Alberta
Edmonton, Alberta, Canada
Not yet recruiting
Canada, British Columbia
Vancouver, British Columbia, Canada
Recruiting
Canada, Manitoba
Winnipeg, Manitoba, Canada
Withdrawn
Canada, Nova Scotia
Halifax, Nova Scotia, Canada
Not yet recruiting
Canada, Ontario
Hamilton, Ontario, Canada
Withdrawn
Canada, Ontario
Toronto, Ontario, Canada
Not yet recruiting
Canada, Ontario
Toronto, Ontario, Canada
Withdrawn
Canada, Quebec
Levis, Quebec, Canada
Recruiting
Canada, Quebec
Montreal, Quebec, Canada
Not yet recruiting
China
Beijing, China
Not yet recruiting
China
Beijing, China
Recruiting
China
Chengdu, China
Not yet recruiting
China
Guangzhou, China
Recruiting
China
Shanghai, China
Recruiting
China
Tianjin, China
Recruiting
China
Tianjin, China
Withdrawn
Czech Republic
Brno, Czech Republic
Not yet recruiting
Czech Republic
Hradec Kralove, Czech Republic
Recruiting
Czech Republic
Ostrava, Czech Republic
Recruiting
Czech Republic
Praha 10, Czech Republic
Recruiting
Czech Republic
Praha 2, Czech Republic
Not yet recruiting
Denmark
Aarhus C, Denmark
Recruiting
Denmark
Copenhagen, Denmark
Recruiting
Denmark
Roskilde, Denmark
Recruiting
Denmark
Vejle, Denmark
Recruiting
Finland
Helsinki, Finland
Recruiting
Finland
Jyväskylä, Finland
Recruiting
Finland
Oulu, Finland
Recruiting
Finland
Turku, Finland
Recruiting
France
Grenoble Cedex 9, France
Recruiting
France
Limoges, France
Recruiting
France
Montpellier, France
Withdrawn
France
Nantes Cedex 1, France
Withdrawn
France
Paris, France
Recruiting
France
Pessac, France
Recruiting
France
Tours, France
Recruiting
France
Villejuif, France
Recruiting
Germany
Bamberg, Germany
Not yet recruiting
Germany
Berlin, Germany
Not yet recruiting
Germany
Dresden, Germany
Not yet recruiting
Germany
Essen, Germany
Not yet recruiting
Germany
Frankfurt, Germany
Not yet recruiting
Germany
Frankfurt / Main, Germany
Withdrawn
Germany
Fulda, Germany
Not yet recruiting
Germany
Hannover, Germany
Withdrawn
Germany
Heidelberg, Germany
Withdrawn
Germany
Jena, Germany
Not yet recruiting
Germany
Mainz, Germany
Withdrawn
Germany
Muenchen, Germany
Not yet recruiting
Germany
Münster, Germany
Not yet recruiting
Germany
Villingen-Schwenningen, Germany
Not yet recruiting
Hungary
Budapest N/A, Hungary
Recruiting
Hungary
Debrecen, Hungary
Recruiting
Hungary
Gyula, Hungary
Recruiting
Hungary
Szekesfehervar, Hungary
Withdrawn
Hungary
Szombathely, Hungary
Recruiting
Hungary
Veszprem, Hungary
Recruiting
Israel
Beer-Sheva, Israel
Not yet recruiting
Israel
Hadera, Israel
Not yet recruiting
Israel
Haifa, Israel
Not yet recruiting
Israel
Nahariya, Israel
Suspended
Israel
Petah Tikva, Israel
Not yet recruiting
Israel
Ramat-Gan, Israel
Not yet recruiting
Israel
Tel Aviv, Israel
Not yet recruiting
Japan
Fukuoka, Japan
Recruiting
Japan
Hiroshima, Japan
Recruiting
Japan
Isehara, Japan
Withdrawn
Japan
Kyoto, Japan
Recruiting
Japan
Nagoya, Japan
Withdrawn
Japan
Nagoya, Japan
Recruiting
Japan
Osaka, Japan
Recruiting
Japan
Sapporo, Japan
Recruiting
Japan
Sendai, Japan
Recruiting
Japan
Suita, Japan
Recruiting
Japan
Tokyo, Japan
Recruiting
Korea, Republic of
Busan, Korea, Republic of
Recruiting
Korea, Republic of
Goyang, Korea, Republic of
Recruiting
Korea, Republic of
Seognam-Si, Kyungki-Do, Korea, Republic of
Withdrawn
Korea, Republic of
Seoul, Korea, Republic of
Recruiting
Mexico
Mexico, Mexico
Withdrawn
Mexico
Mexico, Mexico
Not yet recruiting
Mexico
Monterrey, Mexico
Recruiting
Mexico
Monterrey, Mexico
Not yet recruiting
Mexico
San Luis Potosi, Mexico
Not yet recruiting
Mexico
Zapopan, Mexico
Withdrawn
Netherlands
Amsterdam Zuidoost, Netherlands
Recruiting
Netherlands
Arnhem, Netherlands
Recruiting
Netherlands
Dordrecht, Netherlands
Recruiting
Netherlands
Groningen, Netherlands
Recruiting
Netherlands
Leiden, Netherlands
Recruiting
Netherlands
Nieuwegein, Netherlands
Recruiting
Netherlands
Rotterdam, Netherlands
Recruiting
Norway
Bergen, Norway
Withdrawn
Norway
Oslo, Norway
Recruiting
Norway
Tromsø, Norway
Recruiting
Poland
Brzozow, Poland
Recruiting
Poland
Chorzów, Poland
Recruiting
Poland
Gdynia, Poland
Suspended
Poland
Krakow, Poland
Recruiting
Poland
Lodz, Poland
Recruiting
Poland
Lublin, Poland
Suspended
Poland
Olsztyn, Poland
Recruiting
Poland
Poznan, Poland
Recruiting
Poland
Warszawa, Poland
Recruiting
Poland
Wroclaw, Poland
Recruiting
Russian Federation
Chelyabinsk, Russian Federation
Withdrawn
Russian Federation
Ekaterinburg, Russian Federation
Completed
Russian Federation
Krasnodar, Russian Federation
Withdrawn
Russian Federation
Moscow, Russian Federation
Recruiting
Russian Federation
Moscow N/A, Russian Federation
Recruiting
Russian Federation
Nizhny Novgorod, Russian Federation
Recruiting
Russian Federation
Rostov-Na-Donu, Russian Federation
Recruiting
Russian Federation
Saint Petersburg, Russian Federation
Withdrawn
Russian Federation
Sochi, Russian Federation
Recruiting
Russian Federation
St. Petersburg, Russian Federation
Recruiting
Russian Federation
Volgograd, Russian Federation
Recruiting
Spain
Barcelona, Spain
Recruiting
Spain
Madrid, Spain
Recruiting
Spain
Madrid, Spain
Withdrawn
Spain
Salamanca, Spain
Recruiting
Spain
Sevilla, Spain
Recruiting
Sweden
Karlstad, Sweden
Withdrawn
Sweden
Linköping, Sweden
Recruiting
Sweden
Luleå, Sweden
Recruiting
Sweden
Lund, Sweden
Not yet recruiting
Sweden
Uppsala, Sweden
Recruiting
Taiwan
Changhua, Taiwan
Withdrawn
Taiwan
Taichung, Taiwan
Recruiting
Taiwan
Tainan, Taiwan
Recruiting
Taiwan
Tainan, Taiwan
Not yet recruiting
Taiwan
Taipei, Taiwan
Withdrawn
Taiwan
Taoyuan County, Taiwan
Recruiting
Turkey
Adana, Turkey
Recruiting
Turkey
Ankara, Turkey
Recruiting
Turkey
Edirne, Turkey
Withdrawn
Turkey
Istanbul, Turkey
Not yet recruiting
Turkey
Izmir, Turkey
Recruiting
Turkey
Kayseri, Turkey
Recruiting
Turkey
Samsun, Turkey
Recruiting
Ukraine
Cherkassy, Ukraine
Recruiting
Ukraine
Dnepropetrovsk, Ukraine
Not yet recruiting
Ukraine
Donetsk, Ukraine
Not yet recruiting
Ukraine
Khmelnitskiy, Ukraine
Recruiting
Ukraine
Kiev, Ukraine
Not yet recruiting
Ukraine
Kiev, Ukraine
Recruiting
Ukraine
Lviv, Ukraine
Recruiting
Ukraine
Makiivka, Ukraine
Recruiting
Ukraine
Simferopol, Ukraine
Not yet recruiting
United Kingdom
Glasgow, United Kingdom
Not yet recruiting
United Kingdom
Liverpool, United Kingdom
Recruiting
United Kingdom
London, United Kingdom
Withdrawn
United Kingdom
London, United Kingdom
Recruiting
United Kingdom
Maidstone, United Kingdom
Not yet recruiting
United Kingdom
Manchester, United Kingdom
Recruiting
United Kingdom
Nottingham, United Kingdom
Recruiting
United Kingdom
Oxford, United Kingdom
Recruiting
United Kingdom
Romford, United Kingdom
Recruiting
United Kingdom
Southampton, United Kingdom
Recruiting